InsidersTradesSigma
ELI LILLY & Co Stock: price and directors' dealings · United States · SEC (Form 4)
Track the ELI LILLY & Co share price and the full insider trade history of the company, a listed equity based in United States. Shares trade on US US, under the authority of SEC (Form 4). Operating in the Healthcare & Pharma sector, ELI LILLY & Co has published 679 insider filings. Market capitalisation: €1,070.1bn. The latest transaction was disclosed on 16 June 2026 (Attribution). Among the most active insiders: LILLY ENDOWMENT INC. The full history is accessible without an account.
679
Insider Decl.
0
Thresholds
€484,995
4 ops.
Buy Volume
€3bn
210 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate ELI LILLY & Co Buy (bullish), based on 28 analysts. Average price target: US$1,220.39.
26Σ signal
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Fundamental score
Ranked 9,324 of 25,791 companies
58.9
score / 100
Value31
Quality86
FCF yld0.6%
Earn yld1.9%
EV/EBITDA35.6x
ROE107%
Gross mgn83%
Net mgn32%
Debt/EBITDA1.3x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
Last declaration on 16 June 2026
Declarations679 total
10.995 sharesCommon StockSEC:0001310215-26-000011:0
8.781 sharesCommon StockSEC:0000059478-26-000057:0
14.094 sharesCommon StockSEC:0000059478-26-000059:0
4.39 sharesCommon StockSEC:0001262388-26-000012:0
2,500 sharesCommon StockSEC:0001826001-26-000006:0
13.498 shares@ US$919.900.0000% mcap0.9% of flowCommon StockSEC:0000059478-26-000034:0
11.062 shares@ US$1,062.190.8% of flowCommon StockSEC:0001310215-25-000012:0
11.5 shares@ US$1,021.700.9% of flowCommon StockSEC:0001310215-25-000010:0
215.327 shares@ US$1,021.7016.0% of flowCommon StockSEC:0001310215-25-000010:1
16.833 shares@ US$698.050.8% of flowCommon StockSEC:0000059478-25-000224:0
15.416 shares@ US$762.180.8% of flowCommon StockSEC:0000059478-25-000182:0
13.011 shares@ US$762.181.0% of flowCommon StockSEC:0000059478-25-000184:0
13.011 shares@ US$762.182.4% of flowCommon StockSEC:0000059478-25-000188:0
6.505 shares@ US$762.180.7% of flowCommon StockSEC:0000059478-25-000194:0
19.462 shares@ US$762.181.4% of flowCommon StockSEC:0000059478-25-000196:0
14.55 shares@ US$807.580.9% of flowCommon StockSEC:0000059478-25-000168:0
19.644 shares@ US$755.111.5% of flowCommon StockSEC:0000059478-25-000152:0
15.561 shares@ US$755.110.9% of flowCommon StockSEC:0000059478-25-000146:0
13.133 shares@ US$755.112.5% of flowCommon StockSEC:0000059478-25-000150:0
6.566 shares@ US$755.110.7% of flowCommon StockSEC:0000059478-25-000154:0
13.133 shares@ US$755.111.1% of flowCommon StockSEC:0000059478-25-000148:0
1,250 shares@ US$749.246.9% of flowCommon StockSEC:0000059478-25-000144:0
17,875 shares0Common StockSEC:0000059478-25-000134:0
25 of 679 declarations
About ELI LILLY & Co
Eli Lilly and Company (NYSE: LLY) is a major U.S.-listed pharmaceutical company headquartered in Indianapolis, Indiana, United States. The company traces its origins to 1876, when Colonel Eli Lilly founded a drug manufacturing business in Indianapolis; Lilly was then incorporated in Indiana in 1901 to succeed that enterprise. Today, Lilly reports in a single operating segment: human pharmaceutical products. Its business model is built around research, development, manufacturing, and global commercialization of innovative medicines. ([investor.lilly.com](https://investor.lilly.com/static-files/84711071-9e5a-47e1-bc74-d0753a2d93a8)) From an equity analysis perspective, Lilly’s portfolio is now dominated by cardiometabolic growth engines, while also retaining meaningful exposure to oncology, immunology, and other specialty therapeutic areas. Key marketed products include Mounjaro and Zepbound, which have become core growth drivers, alongside Trulicity, Humalog, Verzenio, Taltz, Jardiance through a collaboration, Jaypirca, and other assets. The company’s pipeline is also closely watched, especially orforglipron, its oral GLP-1 candidate that has become one of the most strategically important programs in the industry. ([investor.lilly.com](https://investor.lilly.com/static-files/84711071-9e5a-47e1-bc74-d0753a2d93a8)) In competitive terms, Lilly is one of the global leaders in incretin-based therapies, competing in a highly contested market with Novo Nordisk and other pharmaceutical peers. Its competitive edge comes from strong clinical execution, a broad late-stage pipeline, manufacturing scale, and a commercial footprint that has allowed it to capture substantial demand in diabetes and obesity. Lilly’s 2024 annual report indicates that Mounjaro, Trulicity, and Zepbound together represented a very large share of total revenue, underscoring how central the cardiometabolic franchise has become to the investment case. ([investor.lilly.com](https://investor.lilly.com/static-files/84711071-9e5a-47e1-bc74-d0753a2d93a8)) Geographically, Lilly has a global presence with sales in the United States and outside the United States, and it continues to invest across major developed markets and selected high-growth regions. Recent company news has reinforced the growth narrative: in 2025 and 2026, Lilly reported multiple positive clinical and regulatory milestones for orforglipron, expanded access and pricing initiatives for Zepbound, and label expansion progress for Jaypirca. Taken together, these developments support the view of Lilly as a high-quality large-cap healthcare franchise with secular growth drivers, strong innovation momentum, and an increasingly important position in global metabolic medicine. ([investor.lilly.com](https://investor.lilly.com/news-releases/news-release-details/zepbound-tirzepatide-most-prescribed-weight-management?utm_source=openai))
